Current stage -Stage II Posts on Medivizor
Navigation Menu

Current stage -Stage II Posts on Medivizor

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Posted by on Sep 27, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of radiation therapy (RT) dose escalation and the addition of short-term (ST) or long-term (LT) androgen deprivation therapy (ADT) to RT in men with localized prostate cancer (PCa). The data showed that the addition of ST or LT-ADT to RT improved survival without metastasis in these patients,...

Read More

Evaluating the benefits of adding androgen deprivation therapy to radiation therapy and extending its duration in men with localized prostate cancer.

Evaluating the benefits of adding androgen deprivation therapy to radiation therapy and extending its duration in men with localized prostate cancer.

Posted by on Aug 14, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT) and the benefit of extending the duration of ADT in men with localized prostate cancer (PCa). The data showed that the addition of ADT to RT and extending the duration of ADT administered after RT significantly improved the survival...

Read More

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Posted by on Jun 5, 2022 in Prostate cancer | 0 comments

In a nutshell This review compared the outcomes of 2 techniques for robotic-assisted radical prostatectomy (RARP; complete removal of the prostate gland using robotic arms): Retzius-sparing (RS)-RARP and conventional (C)-RARP in patients with localized prostate cancer (PCa). The analysis showed that RS-RARP was associated with improved urinary...

Read More

Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.

Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.

Posted by on May 31, 2022 in Prostate cancer | 0 comments

In a nutshell The study evaluated the effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) to androgen-deprivation therapy (ADT) in patients with high-risk non-metastatic prostate cancer (PC). The data showed that AAP added to ADT significantly improved survival...

Read More

Evaluating the effectiveness and safety outcomes of second radiation therapy in patients with locally recurrent prostate cancer.

Evaluating the effectiveness and safety outcomes of second radiation therapy in patients with locally recurrent prostate cancer.

Posted by on Oct 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of re-irradiation for the treatment of patients with locally recurrent prostate cancer. The data showed that the use of re-irradiation in these patients was associated with good outcomes and low toxicity. Some background Radiotherapy (RT) is an effective treatment for localized...

Read More

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Posted by on Aug 22, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the role of 18F-fluciclovine-PET-CT versus conventional imaging (bone scan and either CT or MRI) alone for salvage radiotherapy (RT) after prostate surgery for the treatment of patients with localized prostate cancer (PCa). The data showed that including 18F-fluciclovine-PET-CT into the decision-making process for RT...

Read More

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients.  Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...

Read More

Does nerve-sparing status impact surgical margin location for recurrence of prostate cancer after prostate surgery?

Does nerve-sparing status impact surgical margin location for recurrence of prostate cancer after prostate surgery?

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This article looked at the impact of nerve-sparing (NS) surgery on positive surgical margin (PSM) location and the recurrence of tumors in patients following radical prostatectomy (RP; prostate removal surgery). The authors found that having NS surgery on both sides of the prostate increased the risk of PSM and was associated with a higher...

Read More

Evaluating the association between the lowest PSA value after prostate surgery and the occurrence of biochemical recurrence in patients with localized prostate cancer

Evaluating the association between the lowest PSA value after prostate surgery and the occurrence of biochemical recurrence in patients with localized prostate cancer

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the association between the lowest PSA value after radical prostatectomy (RP; surgery to remove the prostate) and the occurrence of biochemical recurrence (BCR) in patients with localized prostate cancer (PCa). The study found that a higher PSA value after RP and a shorter time to reach this...

Read More

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell The study aimed to understand the long-term outcomes of focal laser therapy (FLT) in patients with prostate cancer. The study showed that this treatment has long-term survival without recurrence in certain patients.   Some background Surgical removal of the prostate gland is often recommended as a treatment for...

Read More

Evaluating the effectiveness and optimal duration of additional androgen deprivation therapy after radiotherapy in locally advanced prostate cancer

Evaluating the effectiveness and optimal duration of additional androgen deprivation therapy after radiotherapy in locally advanced prostate cancer

Posted by on Apr 25, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes and effectiveness of administering additional (adjuvant) androgen deprivation therapy (A-ADT) for long-term after radiotherapy (RT) in high-risk or very high-risk locally advanced prostate cancer (LAPC). The study found that the addition of A-ADT longer than 1 year after RT showed good treatment outcomes...

Read More

Evaluating the effectiveness of tadalafil for the treatment of lower urinary tract symptoms and erectile dysfunction after low-dose-rate brachytherapy for prostate cancer

Evaluating the effectiveness of tadalafil for the treatment of lower urinary tract symptoms and erectile dysfunction after low-dose-rate brachytherapy for prostate cancer

Posted by on Mar 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness of phosphodiesterase-5 (PDE5) inhibitor tadalafil (Cialis) for the treatment of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) after low-dose-rate (LDR) brachytherapy (BT) in patients with localized prostate cancer. The data showed that tadalafil improved the LUTS and ED outcomes...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2022 Medivizor